Medexus Pharmaceuticals Inc.
MEDXF
$1.77
-$0.01-0.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.99M | 26.30M | 27.28M | 25.96M | 25.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.99M | 26.30M | 27.28M | 25.96M | 25.21M |
| Cost of Revenue | 13.11M | 10.66M | 11.10M | 11.27M | 11.13M |
| Gross Profit | 16.89M | 15.65M | 16.19M | 14.69M | 14.08M |
| SG&A Expenses | 10.97M | 9.69M | 10.35M | 10.37M | 10.69M |
| Depreciation & Amortization | 1.76M | 1.58M | 1.41M | 1.45M | 1.45M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.21M | 22.20M | 22.95M | 23.14M | 23.64M |
| Operating Income | 3.78M | 4.10M | 4.33M | 2.83M | 1.57M |
| Income Before Tax | 880.00K | -581.00K | 1.90M | 990.00K | -795.00K |
| Income Tax Expenses | 147.00K | -691.00K | -57.00K | 228.00K | -261.00K |
| Earnings from Continuing Operations | 733.00K | 110.00K | 1.96M | 762.00K | -534.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 733.00K | 110.00K | 1.96M | 762.00K | -534.00K |
| EBIT | 3.78M | 4.10M | 4.33M | 2.83M | 1.57M |
| EBITDA | 5.54M | 5.68M | 5.70M | 4.24M | 3.02M |
| EPS Basic | 0.03 | 0.00 | 0.08 | 0.03 | -0.02 |
| Normalized Basic EPS | 0.02 | 0.05 | 0.06 | 0.08 | -0.02 |
| EPS Diluted | 0.03 | 0.00 | 0.08 | 0.03 | -0.02 |
| Normalized Diluted EPS | 0.02 | 0.05 | 0.06 | 0.07 | -0.02 |
| Average Basic Shares Outstanding | 24.68M | 24.55M | 24.46M | 24.45M | 24.18M |
| Average Diluted Shares Outstanding | 24.68M | 24.55M | 24.46M | 25.11M | 24.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |